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A BS TR AC T
BACKGROUND
Vorapaxar is a new oral protease-activated–receptor 1 (PAR-1) antagonist that inhibits 
thrombin-induced platelet activation.
METHODS
In this multinational, double-blind, randomized trial, we compared vorapaxar with 
placebo in 12,944 patients who had acute coronary syndromes without ST-segment 
elevation. The primary end point was a composite of death from cardiovascular causes, 
myocardial infarction, stroke, recurrent ischemia with rehospitalization, or urgent 
coronary revascularization.
RESULTS
Follow-up in the trial was terminated early after a safety review. After a median follow-up 
of 502 days (interquartile range, 349 to 667), the primary end point occurred in 1031 
of 6473 patients receiving vorapaxar versus 1102 of 6471 patients receiving placebo 
(Kaplan–Meier 2-year rate, 18.5% vs. 19.9%; hazard ratio, 0.92; 95% confidence in-
terval [CI], 0.85 to 1.01; P = 0.07). A composite of death from cardiovascular causes, 
myocardial infarction, or stroke occurred in 822 patients in the vorapaxar group 
versus 910 in the placebo group (14.7% and 16.4%, respectively; hazard ratio, 0.89; 
95% CI, 0.81 to 0.98; P = 0.02). Rates of moderate and severe bleeding were 7.2% in the 
vorapaxar group and 5.2% in the placebo group (hazard ratio, 1.35; 95% CI, 1.16 to 1.58; 
P<0.001). Intracranial hemorrhage rates were 1.1% and 0.2%, respectively (hazard 
ratio, 3.39; 95% CI, 1.78 to 6.45; P<0.001). Rates of nonhemorrhagic adverse events 
were similar in the two groups.
CONCLUSIONS
In patients with acute coronary syndromes, the addition of vorapaxar to standard 
therapy did not significantly reduce the primary composite end point but signifi-
cantly increased the risk of major bleeding, including intracranial hemorrhage. 
(Funded by Merck; TRACER ClinicalTrials.gov number, NCT00527943.)
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The risk of recurrent ischemic com-plications among patients with acute coro-nary syndromes without ST-segment eleva-
tion remains high despite contemporary treatment 
strategies, including the use of early revascular-
ization and dual antiplatelet therapy.1,2 Hence, the 
assessment of new platelet inhibitors has contin-
ued to be an important avenue of investigation.3-5
Thrombin activates platelets through two 
protease-activated receptors (PARs), PAR-1 and 
PAR-4.6 PAR-1 is activated by lower concentra-
tions of thrombin than PAR-4 and mediates a 
more rapid platelet-activation response.7 In pre-
clinical models, selective PAR-1 blockade result-
ed in potent inhibition of thrombin-induced 
platelet aggregation but appeared to preserve 
primary hemostatic function.8
Vorapaxar (SCH 530348, Merck) is an oral 
competitive PAR-1 antagonist that inhibits 
thrombin-induced platelet aggregation. In two 
phase 2 trials involving patients undergoing elec-
tive percutaneous coronary intervention (PCI) and 
in those with acute coronary syndromes without 
ST-segment elevation receiving dual antiplatelet 
therapy, vorapaxar (with loading doses up to 40 mg 
and maintenance doses up to 2.5 mg) did not sig-
nificantly increase the risk of bleeding as compared 
with placebo, whereas a trend toward fewer myo-
cardial infarctions was observed.9,10 We conducted 
a multinational, randomized, double-blind, placebo-
controlled study, the Thrombin Receptor Antago-
nist for Clinical Event Reduction in Acute Coronary 
Syndrome (TRACER) trial, to determine whether 
the addition of vorapaxar to standard therapy 
would be superior to placebo in reducing recur-
rent ischemic cardiovascular events and to deter-
mine its safety profile in patients with acute coro-
nary syndromes without ST-segment elevation.
ME THODS
STUDY DESIGN AND ORGANIZATION
Details of the study design and organization 
have been published previously.11 The trial was 
funded by Merck. A consortium of international 
academic research organizations, led by the Duke 
Clinical Research Institute in collaboration with 
the sponsor, designed and conducted the study, 
collected the data, and performed the analyses.12 
An academically led executive committee super-
vised the trial design and operations (see the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org). The study proto-
col is also available at NEJM.org. The steering com-
mittee consisted of representa tives from all par-
ticipating countries. Analyses presented in this 
article were performed independently at the Duke 
Clinical Research Institute with the use of the 
raw data. The first author drafted the manu-
script, and all the authors contributed to its revi-
sion. The study was approved by the appropriate 
national and institutional regulatory authorities 
and ethics committees. The executive committee 
made the decision to submit the manuscript for 
publication.
STUDY PARTICIPANTS
Patients were eligible if they had had acute symp-
toms of coronary ischemia within 24 hours be-
fore hospital presentation and at least one of the 
following findings: a cardiac troponin (I or T) or 
creatine kinase MB (CK-MB) level that was high-
er than the upper limit of the normal range or 
new ST-segment depression of more than 0.1 mV 
or transient ST-segment elevation (<30 minutes) 
of more than 0.1 mV in at least two contiguous 
leads. Also required were one or more of the fol-
lowing four criteria: an age of at least 55 years; 
previous myocardial infarction, PCI, or coronary-
artery bypass grafting (CABG); diabetes mellitus; 
or peripheral arterial disease. A complete list of 
inclusion and exclusion criteria is provided in the 
Supplementary Appendix. All patients provided 
written informed consent.
STUDY PROCEDURES
Patients were randomly assigned in a 1:1 ratio to 
receive vorapaxar (at a loading dose of 40 mg and 
a daily maintenance dose of 2.5 mg thereafter) or 
matching placebo with stratification according 
to the intention to use a glycoprotein IIb/IIIa in-
hibitor (vs. none) and the intention to use a par-
enteral direct thrombin inhibitor (vs. other anti-
thrombin agents). Study-group assignment was 
performed with the use of a 24-hour automated 
voice-response system. The loading dose was to 
be given immediately after randomization and at 
least 1 hour before any coronary revasculariza-
tion procedure. The maintenance dose was to be 
continued for the entire duration of the study, 
with a planned minimum of 1 year. Investigators 
were encouraged to follow current practice 
guidelines of professional societies.1,2 Therefore, 
it was anticipated that the majority of patients 
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would be treated with a combination of aspirin 
and a P2Y12 inhibitor.
Follow-up assessment was performed during 
the index hospitalization and at 1 month, 4 months, 
8 months, 12 months, and every 6 months there-
after. A final visit was scheduled at the end of 
the study. Patients who prematurely discontin-
ued treatment were followed by telephone at the 
same intervals. The recruitment period began on 
December 18, 2007, and ended on June 4, 2010. 
In selected centers participating in a substudy of 
pharmacokinetics and pharmacodynamics and in 
China, an additional 340 patients were recruited up 
to November 30, 2010, to achieve enrollment goals. 
Follow-up of these patients was to be completed 
simultaneously with that of the main cohort.
END POINTS
The primary efficacy end point was a composite 
of death from cardiovascular causes, myocardial 
infarction, stroke, recurrent ischemia with re-
hospitalization, or urgent coronary revascular-
ization. The prespecified key secondary end 
point was a composite of death from cardiovas-
cular causes, myocardial infarction, or stroke. 
Other efficacy end points were exploratory. The 
main safety end points were a composite of mod-
erate or severe bleeding according to the Global 
Table 1. Baseline Demographic and Clinical Characteristics of the Patients.*
Characteristic
Placebo
(N = 6471)
Vorapaxar
(N = 6473)
Age
Median — yr 64.0 64.0
Interquartile range — yr 58.0–72.0 58.0–71.0
≥75 yr — no. (%) 1096 (16.9) 1110 (17.1)
Female sex — no. (%) 1822 (28.2) 1810 (28.0)
Race or ethnic group — no./total no. (%)†
White 5510/6453 (85.4) 5529/6456 (85.6)
Black 161/6453 (2.5) 151/6456 (2.3)
Asian 533/6453 (8.3) 523/6456 (8.1)
Other 249/6453 (3.9) 253/6456 (3.9)
Body weight — kg
Median 80.0 80.4
Interquartile range 70.0–92.0 70.0–93.0
Region of enrollment — no. (%)
North America 1694 (26.2) 1710 (26.4)
South America 420 (6.5) 428 (6.6)
Western Europe 2930 (45.3) 2909 (44.9)
Eastern Europe 742 (11.5) 745 (11.5)
Asia 474 (7.3) 462 (7.1)
Australia or New Zealand 211 (3.3) 219 (3.4)
Cardiovascular risk factors — no./total no. (%)
Hypertension 4591/6469 (71.0) 4537/6470 (70.1)
Hyperlipidemia 4024/6469 (62.2) 4038/6470 (62.4)
Diabetes mellitus 2030/6469 (31.4) 2040/6470 (31.5)
Current tobacco use 1787/6469 (27.6) 1749/6470 (27.0)
Creatinine clearance — no./total no. (%)
<30 ml/min 88/6120 (1.4) 102/6141 (1.7)
30–60 ml/min 743/6120 (12.1) 734/6141 (12.0)
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Use of Strategies to Open Occluded Coronary Ar-
teries (GUSTO) classification and clinically sig-
nificant bleeding according to the Thrombolysis 
in Myocardial Infarction (TIMI) classification, 
defined as TIMI major or minor bleeding or 
bleeding that required unplanned medical or 
surgical treatment or laboratory evaluation.13,14 
End-point definitions are provided in the Supple-
mentary Appendix. A central clinical-events com-
mittee, whose members were unaware of the 
study-group assignments, assessed all suspected 
efficacy and bleeding events.
STATISTICAL ANALYSIS
The primary hypothesis was that vorapaxar 
would be superior to standard therapy alone for 
the prevention of cardiac ischemic events. The 
trial was prospectively designed and powered to 
detect significant differences in both the primary 
end point and the key secondary end point. To 
account for multiplicity, the primary end point 
and the key secondary end point were tested in 
sequence. If superiority was not achieved for the 
primary end point, it could not be declared for 
the key secondary end point. After an interim 
Table 1. (Continued.)
Characteristic
Placebo
(N = 6471)
Vorapaxar
(N = 6473)
Cardiovascular disease history — no./total no. (%)
Myocardial infarction 1890/6469 (29.2) 1901/6470 (29.4)
PCI 1531/6467 (23.7) 1559/6467 (24.1)
CABG 766/6467 (11.8) 777/6467 (12.0)
Stroke 262/6469 (4.1) 291/6470 (4.5)
Peripheral arterial disease 468/6469 (7.2) 468/6470 (7.2)
Positive for troponin or creatine kinase MB — no./total no. (%) 6037/6429 (93.9) 6013/6428 (93.5)
Electrocardiographic findings — no. (%)
ST-segment depression 2122 (32.8) 2077 (32.1)
ST-segment elevation‡ 378 (5.8) 358 (5.5)
TIMI risk score — no. (%)§
0–2 27 (0.4) 40 (0.6)
3–4 3357 (51.9) 3341 (51.6)
5–7 3087 (47.7) 3092 (47.8)
Killip class — no./total no. (%)¶
II 260/6415 (4.1) 234/6417 (3.6)
III or IV 61/6415 (1.0) 69/6417 (1.1)
Stratification factor — no. (%)
Intention to use glycoprotein IIb/IIIa inhibitor 1345 (20.8) 1365 (21.1)
Intention to use direct thrombin inhibitor 1098 (17.0) 1058 (16.3)
Use of antiplatelet drugs — no./total no. (%)
Thienopyridine 5639/6471 (87.1) 5668/6473 (87.6)
Aspirin 6272/6471 (96.9) 6243/6473 (96.4)
≤100 mg 3778/6272 (60.2) 3745/6243 (60.0)
>100 mg 2494/6272 (39.8) 2498/6243 (40.0)
* There were no significant differences between the groups. CABG denotes coronary-artery bypass grafting, and PCI per-
cutaneous coronary intervention.
† Race or ethnic group was reported by investigators after interviews with patients.
‡ Patients with transient (<30 min) ST-segment elevation were eligible.
§ The Thrombolysis in Myocardial Infarction (TIMI) risk score ranges from 0 to 7, with higher scores indicating greater risk.
¶ According to the Killip classification, class II indicates cardiac S3 or rales on 50% or less of the lung fields, class III indicates 
rales on more than 50% of the lung fields, and class IV indicates signs of cardiogenic shock.
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assessment of aggregated event rates, and after 
approximately 6500 subjects had been enrolled, 
the planned sample size was increased from 
10,000 to approximately 12,500 patients. We cal-
culated that a minimum of 1900 primary end-
point events would provide a power of more than 
95% to detect a 15% hazard reduction in the 
vorapaxar group, as compared with the placebo 
group, and 1457 key secondary end-point events 
would provide a power of 90% to detect a 15% 
hazard reduction.
Efficacy analyses were performed according 
to study-group assignments on the basis of the 
time to the first occurrence of any component of 
the composite end points. Estimates of the haz-
ard ratios and 95% confidence intervals for vora-
paxar as compared with placebo were calculated 
with the use of a Cox proportional-hazards model 
in which study-group assignment and stratifica-
tion factors were included as covariates. Patients 
were followed until the final visit or the last as-
sessment of end points.
A planned formal interim analysis was per-
formed on June 25, 2010, which resulted in the 
continuation of the study as planned. To account 
for the formal interim analysis, the significance 
level was adjusted on the basis of the O’Brien–
Fleming method. A significance level of 0.049 
was used for the analysis of the primary and key 
secondary efficacy end points at the end of the 
study. The safety analyses, which included patients 
who received at least one dose of a study drug, 
were performed with the use of a Cox model for 
the period in which the study drug was received. 
Event rates are presented as 2-year Kaplan–Meier 
estimates, unless otherwise specified. Continuous 
data are provided as medians with interquartile 
ranges. The statistical analysis plan is available 
at NEJM.org.
R ESULT S
STUDY PARTICIPANTS AND FOLLOW-uP
A total of 12,944 patients at 818 sites in 37 coun-
tries were enrolled. After an unplanned safety 
review on January 8, 2011, the data and safety 
monitoring board recommended that the trial be 
stopped rather than continue as planned until 
Table 2. Treatment during Index Hospitalization.
Variable
Placebo
(N = 6471)
Vorapaxar
(N = 6473)
Time from symptom onset to randomization — hr
Median 26.9 26.7
Interquartile range 7.6–50.2 17.6–48.7
Time from arrival at hospital to randomization — hr
Median 21.1 21.2
Interquartile range 12.2–41.1 12.2–40.6
Time from randomization to first dose of study drug — min
Median 21.0 21.0
Interquartile range 10.0–42.0 10.0–43.0
Receipt of randomized treatment — no. (%) 6441 (99.5) 6446 (99.6)
Discontinuation before the end of the study or death — no./total no. (%) 1726/6441 (26.8) 1818/6446 (28.2)
Adverse event 489/1726 (28.3) 649/1818 (35.7)
Reason unrelated to assigned study treatment 865/1726 (50.1) 858/1818 (47.2)
Noncompliance with protocol 287/1726 (16.6) 232/1818 (12.8)
Did not have disease of interest 65/1726 (3.8) 56/1818 (3.1)
Unknown reason 20/1726 (1.2) 23/1818 (1.3)
Exposure to randomized treatment — days
Median 393.0 379.0
Interquartile range 236.0–588.0 231.0–585.0
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June 4, 2011. The protocol-defined target num-
ber of primary efficacy end points had been 
reached. In addition, the board recommended 
termination of study medication in patients with 
a history of stroke who had been enrolled in an 
independent companion trial involving patients 
with chronic vascular disease.15 On January 13, 
2011, sites were notified that they should tell all 
patients to stop taking the assigned study drug 
and schedule a final visit.
Baseline demographic characteristics were well 
balanced between the two study groups (Table 1). 
The median follow-up period was 502 days (in-
terquartile range, 349 to 667) (see the Supple-
mentary Appendix). A total of 761 patients (5.9%) 
declined to continue participation during follow-
up. This group included patients who withdrew 
their consent to any trial assessment, those who 
agreed to be contacted at the end of the study for 
a vital-status assessment, and those who were 
lost to follow-up. Within this group, vital status 
was assessed in 512 patients at the end of the 
study. Overall, only 15 patients (0.1%) were lost 
to follow-up (see the Supplementary Appendix).
STUDY DRUG AND CONCOMITANT THERAPIES
Patients underwent randomization a median of 
21.2 hours (interquartile range, 12.2 to 40.8) after 
hospitalization (Table 2). The median exposure to 
a study drug was 386 days (interquartile range, 
233 to 586). Rates of study-drug discontinuation 
were slightly higher in the vorapaxar group than 
in the placebo group (28.2% vs. 26.8%).
Clopidogrel was administered in 91.8% of 
patients during the index hospitalization, and 
cardiac catheterization was performed in 88.1% 
of patients, PCI in 57.8%, and CABG in 10.1% 
(Table 2). The loading dose of the assigned study 
drug was given a median of 3.5 hours (inter-
quartile range, 1.8 to 20.7) before PCI.
Table 2. (Continued.)
Variable
Placebo
(N = 6471)
Vorapaxar
(N = 6473)
Cardiac catheterization — no./total no. (%) 5689/6471 (87.9) 5710/6473 (88.2)
PCI — no./total no. (%)
Any 3715/6471 (57.4) 3764/6473 (58.1)
Performed ≤24 hr after randomization 2929/3715 (78.8) 2982/3764 (79.2)
Stenting during index PCI — no./total no. (%)
Any 3526/3715 (94.9) 3549/3764 (94.3)
Drug-eluting stent 2042/3526 (57.9) 1973/3549 (55.6)
Bare-metal stent 1636/3526 (46.4) 1732/3549 (48.8)
Interval between administration of loading dose of study drug  
and PCI — hr
Median 3.5 3.5
Interquartile range 1.8–20.8 1.8–20.6
CABG
Any — no. (%) 673 (10.4) 639 (9.9)
Interval between administration of loading dose of study drug  
and CABG — hr
Median 118.9 120.0
Interquartile range 48.0–214.4 47.3–194.1
Discontinuation of study drug before CABG — no./total no. (%) 153/673 (22.7) 165/639 (25.8)
Antiplatelet use — no. (%)
Clopidogrel 5933 (91.7) 5950 (91.9)
Aspirin 6415 (99.1) 6410 (99.0)
Glycoprotein IIb/IIIa inhibitor 1349 (20.8) 1352 (20.9)
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PRIMARY AND KEY SECONDARY END POINTS
One of the components of the primary end point 
(a composite of death from cardiovascular causes, 
myocardial infarction, stroke, recurrent ischemia 
with rehospitalization, or urgent coronary revas-
cularization) occurred in 1031 of 6473 patients in 
the vorapaxar group and in 1102 of 6471 patients 
in the placebo group, corresponding to a 2-year 
rate of 18.5% in the vorapaxar group and 19.9% in 
the placebo group (hazard ratio in the vorapaxar 
group, 0.92; 95% confidence interval [CI], 0.85 to 
1.01; P = 0.07) (Fig. 1A and Table 3).
The key secondary end point (a composite of 
death from cardiovascular causes, myocardial in-
farction, or stroke) occurred in 822 patients in the 
vorapaxar group and 910 patients in the placebo 
group, for 2-year Kaplan–Meier estimates of 14.7% 
and 16.4%, respectively (hazard ratio, 0.89; 95% CI, 
0.81 to 0.98; P = 0.02) (Fig. 1B and Table 3). Among 
the individual components of the efficacy end 
points, the reduction in the rate of myocardial 
infarction was the main effect observed in the 
vorapaxar group, as compared with the placebo 
group (11.1% vs. 12.5% at 2 years; hazard ratio, 
0.88; 95% CI, 0.79 to 0.98; P = 0.02). A reduction in 
the rate of type 1 (spontaneous) myocardial in-
farction16 in the vorapaxar group largely accounted 
for the difference (5.6% vs. 6.8%).
OTHER EFFICACY END POINTS
The composite end point of death from cardio-
vascular causes or myocardial infarction also oc-
curred less frequently in the vorapaxar group 
than in the placebo group (13.5% vs. 14.9%; haz-
ard ratio, 0.90; 95% CI, 0.81 to 0.99; P = 0.03) 
(Table 3). The rates of death from any cause were 
6.5% in the vorapaxar group and 6.1% in the pla-
cebo group (hazard ratio, 1.05; 95% CI, 0.90 to 
1.23; P = 0.52).
Among patients who underwent placement of 
a stent during the index hospitalization, the 
rates of definite or probable stent thrombosis 
were similar in the two groups: 1.7% in the 
vorapaxar group and 1.5% in the placebo group 
(hazard ratio, 1.12; 95% CI, 0.78 to 1.62; 
P = 0.54). Overall, stroke rates were similar in the 
two groups. However, the 2-year rate of is-
chemic stroke was lower in the vorapaxar group 
(1.1%) than in the placebo group (1.4%), whereas 
the rate of hemorrhagic stroke was higher in 
the vorapaxar group (0.3%) than in the placebo 
group (0.1%).
BLEEDING OUTCOMES
Vorapaxar increased the rate of GUSTO moderate 
or severe bleeding, as compared with placebo 
(7.2% vs. 5.2%; hazard ratio, 1.35; 95% CI, 1.16 
to 1.58; P<0.001) (Table 4 and Fig. 2A). The rate 
of clinically significant TIMI bleeding was in-
creased among patients treated with vorapaxar 
(20.2% vs. 14.6%; hazard ratio, 1.43; 95% CI, 1.31 
to 1.57; P<0.001) (Table 4 and Fig. 2B). The excess 
bleeding events continued to accrue during fol-
low-up. The vorapaxar group also had higher 
rates of GUSTO severe bleeding (2.9% vs. 1.6%; 
hazard ratio, 1.66; 95% CI, 1.27 to 2.16; P<0.001), 
TIMI major bleeding (4.0% vs. 2.5%; hazard ra-
tio, 1.53; 95% CI, 1.24 to 1.90; P<0.001), and in-
tracranial hemorrhage (1.1% vs. 0.2%; hazard 
ratio, 3.39; 95% CI, 1.78 to 6.45; P<0.001), with 
an incremental risk over time (Table 4 and the 
Supplementary Appendix). Rates of CABG-relat-
ed bleeding during the index hospitalization did 
not differ significantly between the two study 
groups, and rates of reoperation for bleeding and 
fatal bleeding were similar.
SUBGROUP ANALYSES
Primary and key secondary efficacy outcomes 
were consistent across subgroups (see the Sup-
plementary Appendix). A trend toward more pro-
nounced efficacy with vorapaxar was observed 
for both the primary and key secondary end 
points in patients who were not treated with thi-
enopyridine at randomization.
Vorapaxar increased rates of bleeding in most 
subgroups (see the Supplementary Appendix). Pa-
tients with lower body weight who received vora-
paxar had a higher risk of GUSTO moderate or 
severe bleeding than did patients with higher body 
weight (P = 0.03 for interaction). The hazard of 
GUSTO moderate or severe bleeding in the vora-
paxar group was not increased in patients who 
were not receiving a thienopyridine at ran dom iza-
tion, whereas the risk was increased in patients 
who were receiving a thienopyridine (hazard ra-
tio, 0.95; 95% CI, 0.65 to 1.40 with no thieno-
pyridine; hazard ratio, 1.45; 95% CI, 1.23 to 1.71 
with thienopyridine; P = 0.04 for interaction).
DISCUSSION
In previous studies, simultaneous inhibition of 
two pathways of platelet activation has been shown 
to reduce the occurrence of recurrent ischemic 
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Figure 1. Study End Points.
Shown are Kaplan–Meier event rates at 2 years in the two study groups for the primary efficacy end point (a com-
posite of death from cardiovascular causes, myocardial infarction, stroke, recurrent ischemia with rehospitalization, 
or urgent coronary revascularization) (Panel A) and the key secondary efficacy end point (a composite of death from 
cardiovascular causes, myocardial infarction, or stroke) (Panel B).
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events in patients with acute coronary syndromes 
but to increase the risk of bleeding complica-
tions.3-5,17 In our study, the addition of PAR-1 in-
hibition with vorapaxar to standard therapy re-
sulted in a nonsignificant relative reduction of 8% 
in the primary end point. Vorapaxar reduced the 
hazard of the key secondary end point (death from 
cardiovascular causes, myocardial infarction, or 
stroke) by 11%, with the 95% confidence interval 
excluding a null effect. However, a hierarchical 
statistical-testing strategy was used to control 
for multiple comparisons, and since superiority 
with respect to the primary end point was not 
achieved, superiority with respect to the key sec-
ondary end point cannot be declared.
The difference in the rates of the composite 
end points was driven by a reduction in the rate 
of myocardial infarction, in particular type 1 
Table 3. Efficacy End Points.* 
End Point Placebo (N = 6471) Vorapaxar (N = 6473)
Hazard Ratio 
(95% CI) P Value
Patients  
with Event
Event Rate  
at 2 Yr†
Patients  
with Event
Event Rate  
at 2 Yr†
no./total no. (%) % (95% CI) no./total no. (%) % (95% CI)
Primary efficacy end point 1102/6471 (17.0) 19.9 (18.7–21.1) 1031/6473 (15.9) 18.5 (17.4–19.7) 0.92 (0.85–1.01) 0.07
Key secondary efficacy end point 910/6471 (14.1) 16.4 (15.3–17.5) 822/6473 (12.7) 14.7 (13.7–15.7) 0.89 (0.81–0.98) 0.02
Other secondary end points
Composite of death from cardio-
vascular causes or myocardial  
infarction
834/6471 (12.9) 14.9 (13.9–16.0) 755/6473 (11.7) 13.5 (12.5–14.5) 0.90 (0.81–0.99) 0.03
Death from cardiovascular causes 207/6471 (3.2) 3.8 (3.2–4.3) 208/6473 (3.2) 3.8 (3.3–4.4) 1.00 (0.83–1.22) 0.96
Myocardial infarction 698/6471 (10.8) 12.5 (11.6–13.5) 621 (9.6) 11.1 (10.2–12.0) 0.88 (0.79–0.98) 0.02
Type of myocardial infarction
Type 1, spontaneous 440/6471 (6.8) 365/6473 (5.6)
Type 2, secondary 24/6471 (0.4) 35/6473 (0.5)
Type 3, with sudden death 2/6471 (<0.1) 0/6473 
Type 4a, associated with PCI 180/6471 (2.8) 163/6473 (2.5)
Type 4b, associated with stent throm-
bosis
40/6471 (0.6) 36/6473 (0.6)
Type 5, associated with CABG 12/6471 (0.2) 20/6473 (0.3)
Stroke
Any 103/6471 (1.6) 2.1 (1.7–2.6) 96/6473 (1.5) 1.9 (1.5–2.3) 0.93 (0.70–1.23) 0.61
Ischemic 93/6471 (1.4) 74/6473 (1.1) 0.79 (0.59–1.08) 0.14
Hemorrhagic 8/6471 (0.1) 22/6473 (0.3) 2.73 (1.22–6.14) 0.02
Urgent coronary revascularization 189/6471 (2.9) 3.5 (3.0–4.0) 203/6473 (3.1) 3.8 (3.2–4.4) 1.07 (0.88–1.31) 0.49
Recurrent ischemia with rehospitalization 69/6471 (1.1) 1.5 (1.1–1.9) 79/6473 (1.2) 1.6 (1.2–2.1) 1.14 (0.83–1.58) 0.42
Death from any cause 318/6471 (4.9) 6.1 (5.4–6.8) 334/6473 (5.2) 6.5 (5.8–7.3) 1.05 (0.90–1.23) 0.52
Stent thrombosis per Academic Research 
Consortium definition
Definite or probable 54/3526 (1.5) 61/3549 (1.7) 1.12 (0.78–1.62) 0.54
Definite 47/3526 (1.3) 50/3549 (1.4)
Probable 7/3526 (0.2) 11/3549 (0.3)
* The primary efficacy end point was a composite of death from cardiovascular causes, myocardial infarction, stroke, recurrent ischemia with 
rehospitalization, or urgent coronary revascularization. The prespecified key secondary end point was a composite of death from cardiovas-
cular causes, myocardial infarction, or stroke.
† Event rates at 2 years were calculated with the use of the Kaplan–Meier method.
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Table 4. Bleeding End Points in the As-Treated Population.* 
End Point Placebo (N = 6441) Vorapaxar (N = 6446)
Hazard Ratio
(95% CI) P Value
Patients  
with Event
Event Rate  
at 2 Yr†
Patients  
with Event
Event Rate  
at 2 Yr†
no./total no. (%) % (95% CI) no./total no. (%) % (95% CI)
GUSTO criteria
Moderate or severe bleeding 290/6441 (4.5) 5.2 (4.6–5.9) 391/6446 (6.1) 7.2 (6.5–8.0) 1.35 (1.16–1.58) <0.001
Severe bleeding 87/6441 (1.4) 1.6 (1.3–2.0) 144/6446 (2.2) 2.9 (2.3–3.4) 1.66 (1.27–2.16) <0.001
TIMI criteria
Clinically significant bleeding 755/6441 (11.7) 14.6 (13.5–15.7) 1065/6446 (16.5) 20.2 (19.0–21.4) 1.43 (1.31–1.57) <0.001
Major bleeding 136/6441 (2.1) 2.5 (2.1–3.0) 208/6446 (3.2) 4.0 (3.4–4.6) 1.53 (1.24–1.90) <0.001
Major or minor bleeding 217/6441 (3.4) 4.0 (3.4–4.6) 337/6446 (5.2) 6.5 (5.8–7.3) 1.56 (1.32–1.85) <0.001
Non-CABG major or minor  
bleeding
153/6441 (2.4) 2.8 (2.4–3.3) 262/6446 (4.1) 5.3 (4.6–6.1) 1.72 (1.41–2.10) <0.001
Non-CABG major bleeding 71/6441 (1.1) 1.3 (1.0–1.7) 131/6446 (2.0) 2.7 (2.2–3.3) 1.85 (1.39–2.47) <0.001
Bleeding not meeting any TIMI  
definition
743/6441 (11.5) 14.5 (13.3–15.6) 982/6446 (15.2) 18.7 (17.5–19.9) 1.35 (1.23–1.48) <0.001
Bleeding requiring medical attention 564/6441 (8.8) 11.2 (10.2–12.2) 784/6446 (12.2) 15.2 (14.1–16.3) 1.41 (1.26–1.57) <0.001
Fatal bleeding 8/6441 (0.1) 0.2 (0.1–0.3) 15/6446 (0.2) 0.4 (0.2–0.5) 1.89 (0.80–4.45) 0.15
Intracranial hemorrhage 12/6441 (0.2) 0.2 (0.1–0.4) 40/6446 (0.6) 1.1 (0.7–1.5) 3.39 (1.78–6.45) <0.001
Location
Subdural 4/6441 (<0.1) 14/6446 (0.2)
Intraparenchymal 7/6441 (0.1) 19/6446 (0.3)
Subarachnoid 0/6441 4/6446 (<0.1)
Unknown 1/6441 (<0.1) 3/6446 (<0.1)
Cause
Spontaneous 6/6441 (<0.1) 21/6446 (0.3)
Traumatic 3/6441 (<0.1) 15/6446 (0.2)
Related to surgery or other  
procedure
1/6441 (<0.1) 3/6446 (<0.1)
Other 2/6441 (<0.1) 1/6446 (<0.1)
Outcome
Fatal 3/6441 (<0.1) 10/6446 (0.2)
Nonfatal 8/6441 (0.1) 28/6446 (0.4)
Contributing to death 1/6441 (<0.1) 2/6446 (<0.1)
Index CABG-related bleeding‡
TIMI major 49/671 (7.3) 62/639 (9.7) 1.34 (0.92–1.95) 0.13
Fatal bleeding 2/671 (0.3) 0/639
Reoperation for bleeding 31/671 (4.6) 30/639 (4.7)
* GUSTO denotes Global Use of Strategies to Open Occluded Coronary Arteries, and TIMI Thrombolysis in Myocardial Infarction.
† Event rates at 2 years were calculated with the use of the Kaplan–Meier method.
‡ The median chest-tube drainage was 308 ml in the placebo group and 350 ml in the vorapaxar group at 8 hours and 580 ml in the placebo 
group and 635 ml in the vorapaxar group at 24 hours, with total drainage of 780 ml in the placebo group and 830 ml in the vorapaxar group.
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Figure 2. Risk of Bleeding.
Shown are Kaplan–Meier event rates at 2 years in the two study groups for Global Use of Strategies to Open Oc-
cluded Coronary Arteries (GUSTO) criteria for moderate or severe bleeding (Panel A) and for Thrombolysis in Myo-
cardial Infarction (TIMI) criteria for clinically significant bleeding (Panel B).
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(spontaneous) myocardial infarction. These find-
ings support a potential clinical effect of PAR-1 
inhibition in reducing thrombosis-mediated cor-
onary events. No effect was observed on stent 
thrombosis. It is possible that PAR-1 inhibition 
in addition to dual antiplatelet therapy does not 
further reduce the risk of stent thrombosis or 
that other factors are contributory, but addi-
tional investigations of PAR-1 inhibition for the 
prevention of stent thrombosis might be consid-
ered. The overall effect of early trial termina-
tion, before the planned completion of 1 year of 
follow-up, is unknown, but the protocol-defined 
number of primary and secondary end points 
had been accrued at the time of termination.
In our study, the addition of vorapaxar to 
standard treatment for patients with acute coro-
nary syndromes significantly increased the oc-
currence of clinically important bleeding, in-
cluding intracranial hemorrhage. The magnitude 
of the increase was not expected on the basis of 
preclinical and phase 2 data, which suggested 
that PAR-1 blockade does not increase the risk of 
bleeding, over and above the risk with aspirin 
and clopidogrel.8-10,18 Rather, the results from our 
study are consistent with previous evidence in-
dicating that more potent antithrombotic ther-
apy incrementally increases the risk of bleed-
ing.3-5,13,19-21 The inhibition of multiple pathways 
in thrombus formation may be associated with 
an unacceptable risk of bleeding, even if it offers 
an improvement in the reduction of ischemic 
events. In the subgroup of patients who were not 
receiving a P2Y12 inhibitor at randomization, the 
hazard of bleeding was not increased, and the 
observed effect on efficacy tended to be more 
pronounced. These observations should be con-
sidered exploratory, and future studies of vora-
paxar in patients not receiving a P2Y12 inhibitor 
might be considered. A comparison of PAR-1 block-
ade with P2Y12 inhibition among patients tak-
ing aspirin might also be considered. Additional 
work is needed to understand platelet aggrega-
tion in the patients in our study and the interplay 
between clinical, genomic, or proteomic factors, 
various biologic pathways, and dose selection.22 
It also remains to be determined whether the 
increase in the rate of intracranial hemorrhage 
was related to intensive antithrombotic therapy 
or whether there is a specific link between PAR-1 
inhibition and intracranial vascular hemosta-
sis.19,23
The duration of vorapaxar therapy in conjunc-
tion with dual antiplatelet therapy may have in-
fluenced the risk–benefit profile, since the rate 
of bleeding continued to increase over time. We 
studied patients for a much longer period than 
that in several previous dual antiplatelet trials.3-5 
The progressive accrual of bleeding events with 
prolonged antiplatelet treatment may alter the 
long-term balance between efficacy and bleed-
ing and is largely unknown beyond 1 year. Re-
cent trials have also shown a lack of benefit and 
excessive bleeding with prolonged dual anti-
platelet therapy.24,25 A better understanding of 
the clinically beneficial duration of antiplatelet 
therapies and the well-described but challenging 
link between bleeding and ischemic events is 
needed. The second phase 3 study of vorapaxar 
— the Thrombin-Receptor Antagonist in Secondary 
Prevention of Atherothrombotic Ischemic Events–
TIMI 50 trial15 (NCT00526474) — is currently 
investigating efficacy and safety in patients with 
chronic atherosclerotic cardiovascular disease, in 
whom the use of dual-antiplatelet regimen is 
typically less common.
In conclusion, vorapaxar, when added to stan-
dard therapy with frequent use of aspirin and 
P2Y12 inhibition, did not significantly reduce the 
composite end point of death from cardiovascu-
lar causes, myocardial infarction, stroke, recur-
rent ischemia with rehospitalization, or urgent 
coronary revascularization among patients with 
acute coronary syndromes without ST-segment 
elevation. A reduction in the key secondary end 
point (death from cardiovascular causes, myo-
cardial infarction, or stroke) was observed, but 
superiority was not declared because a signifi-
cant reduction in the primary end point was not 
achieved. Vorapaxar significantly increased bleed-
ing, including major bleeding and intracranial 
hemorrhage. Future research may lead to a better 
understanding of whether different strategies of 
PAR-1 blockade may improve outcomes in pa-
tients with coronary artery disease.
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